List of investigational sexual dysfunction drugs

Investigational sexual dysfunction drugs are pharmaceuticals in various stages of clinical trials or pre-clinical development aimed at treating sexual dysfunction disorders. Sexual dysfunction can affect both men and women, leading to problems such as erectile dysfunction, decreased libido, and other issues affecting sexual health and performance. This article provides an overview of some of the notable investigational drugs targeting these conditions, highlighting their mechanisms of action, the stage of development, and the specific sexual dysfunction they aim to treat.

Erectile Dysfunction

Erectile dysfunction (ED) is a common condition characterized by the inability to develop or maintain an erection of the penis during sexual activity. Several investigational drugs are under development to address ED with novel mechanisms of action or improved safety profiles over existing treatments.

Udenafil

Udenafil is a phosphodiesterase type 5 (PDE5) inhibitor being studied for its potential in treating erectile dysfunction. Similar to other drugs in its class, udenafil works by increasing blood flow to the penis, facilitating erection.

Avanafil

Avanafil is another investigational drug in the class of PDE5 inhibitors. It is designed to work faster and have fewer side effects than its predecessors, offering potential benefits for individuals with ED.

Female Sexual Interest/Arousal Disorder

Female Sexual Interest/Arousal Disorder (FSIAD) is characterized by a lack of sexual interest or arousal, causing distress or interpersonal difficulties. Investigational drugs for FSIAD aim to enhance sexual desire and arousal in women.

Bremelanotide

Bremelanotide is a peptide being investigated for the treatment of FSIAD. It acts on the central nervous system to increase sexual desire in women.

Flibanserin

Flibanserin, initially developed as an antidepressant, is under investigation for treating FSIAD. It works by modifying serotonin levels in the brain, which can affect sexual desire.

Premature Ejaculation

Premature ejaculation (PE) is a condition where ejaculation happens sooner during sexual intercourse than desired. Investigational drugs for PE aim to increase the time between penetration and ejaculation.

Dapoxetine

Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) specifically being studied for the treatment of premature ejaculation. It works by increasing serotonin levels in the nervous system, delaying ejaculation.

Hypoactive Sexual Desire Disorder

Hypoactive Sexual Desire Disorder (HSDD) is a condition characterized by a lack or absence of sexual desires or fantasies, which causes personal distress. Investigational drugs for HSDD aim to increase libido.

Testosterone Therapy

Testosterone therapy in the form of patches, gels, or injections is being investigated for both men and women with HSDD. Testosterone is a hormone that plays a key role in sexual desire.

Conclusion

Investigational sexual dysfunction drugs offer hope for individuals with various sexual disorders. As research progresses, these drugs may provide new treatment options that are more effective or have fewer side effects than currently available therapies.

This list is incomplete; you can help WikiMD by expanding it.